EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect

Linnea Højer Wang, Markus Wehland iD, Petra M Wise, Manfred Infanger, Daniela Grimm iD, Michael C Kreissl iD

International Journal of Molecular Sciences · 24.01.2023 · 24 (3) · 2312

DOI: 10.3390/ijms24032312 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.01.2023. Verfasst von Linnea Højer Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Ole Worms Allé 4, 8000 Aarhus, Denmark. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Thyroid Neoplasms, Hypertension. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Zentrum für Luft-und Raumfahrt (DLR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hypertension, a well-known adverse effect (AE) of these TKIs. Taken together, TKI-induced hypertension is rarely a dose-limiting side effect. However, with increasing survival times of patients under treatment, hypertension-associated complications can be expected to be on the rise without proper medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineThyroid NeoplasmsHypertensionHumansProtein Kinase InhibitorsPiperidinesPyrazolesPyridinesPyrimidinesAnilides

Stichwörter der Autor:innen

adverse effectscabozantinibclinical trialshypertensionmedullary thyroid cancerpralsetinibselpercatinibtyrosine kinase inhibitorsvandetanib

Substanzen

Protein Kinase InhibitorsPiperidinesselpercatinibPyrazolesPyridinespralsetinibPyrimidinescabozantinibAnilides

Autor:innen und Institutionen

  • Department of Biomedicine, Aarhus University, Ole Worms Allé 4, 8000 Aarhus, Denmark.
  • Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, Universitätsplatz 2, 39106 Magdeburg, Germany.
  • Clinic for Plastic, Aesthetic and Hand Surgery, Otto von Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.
  • Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, Otto von Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany.

ORCID-Profile: Markus Wehland, Daniela Grimm, Michael C Kreissl

Förderung

  • Deutsches Zentrum für Luft-und Raumfahrt (DLR)

Zitieren

APA

Højer Wang, L., Wehland, M., Wise, P. M., Infanger, M., Grimm, D., & Kreissl, M. C. (2023). Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. International Journal of Molecular Sciences, 24(3), 2312. https://doi.org/10.3390/ijms24032312

Vancouver

Højer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. International Journal of Molecular Sciences. 2023;24(3):2312. doi:10.3390/ijms24032312

BibTeX
@article{HjerWang2023,
  author = {Højer Wang, Linnea and Wehland, Markus and Wise, Petra M and Infanger, Manfred and Grimm, Daniela and Kreissl, Michael C},
  title = {Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2312},
  doi = {10.3390/ijms24032312}
}
Kostenlos starten →